Nanotechnology for Pediatric Retinoblastoma Therapy
Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocol...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/9/1087 |
| _version_ | 1797483759836069888 |
|---|---|
| author | Eleonora Russo Andrea Spallarossa Bruno Tasso Carla Villa Chiara Brullo |
| author_facet | Eleonora Russo Andrea Spallarossa Bruno Tasso Carla Villa Chiara Brullo |
| author_sort | Eleonora Russo |
| collection | DOAJ |
| description | Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocols are applied. In more advanced forms of the disease, surgical removal of the entire globe and its intraocular contents (enucleation) is, unfortunately, necessary, whereas in other cases, conventional chemotherapy is normally used. To overcome the side-effects and reduced efficacy of traditional chemotherapic drugs, nanodelivery systems that ensure a sustained drug release and manage to reach the target site have more recently been developed. This review takes into account the current use and advances of nanomedicine in the treatment of retinoblastoma and discusses nanoparticulate formulations that contain conventional drugs and natural products. In addition, future developments in retinoblastoma treatment are discussed. |
| first_indexed | 2024-03-09T22:52:38Z |
| format | Article |
| id | doaj.art-c87122f74f644bd1bcb84b07f95a7290 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T22:52:38Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-c87122f74f644bd1bcb84b07f95a72902023-11-23T18:18:22ZengMDPI AGPharmaceuticals1424-82472022-08-01159108710.3390/ph15091087Nanotechnology for Pediatric Retinoblastoma TherapyEleonora Russo0Andrea Spallarossa1Bruno Tasso2Carla Villa3Chiara Brullo4Section of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, Viale Benedetto XV, 3-16132 Genova, ItalySection of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, Viale Benedetto XV, 3-16132 Genova, ItalySection of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, Viale Benedetto XV, 3-16132 Genova, ItalySection of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, Viale Benedetto XV, 3-16132 Genova, ItalySection of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, Viale Benedetto XV, 3-16132 Genova, ItalyRetinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocols are applied. In more advanced forms of the disease, surgical removal of the entire globe and its intraocular contents (enucleation) is, unfortunately, necessary, whereas in other cases, conventional chemotherapy is normally used. To overcome the side-effects and reduced efficacy of traditional chemotherapic drugs, nanodelivery systems that ensure a sustained drug release and manage to reach the target site have more recently been developed. This review takes into account the current use and advances of nanomedicine in the treatment of retinoblastoma and discusses nanoparticulate formulations that contain conventional drugs and natural products. In addition, future developments in retinoblastoma treatment are discussed.https://www.mdpi.com/1424-8247/15/9/1087retinoblastomaconventional chemotherapycancerpediatric rare diseasenanoparticlenanomedicine |
| spellingShingle | Eleonora Russo Andrea Spallarossa Bruno Tasso Carla Villa Chiara Brullo Nanotechnology for Pediatric Retinoblastoma Therapy Pharmaceuticals retinoblastoma conventional chemotherapy cancer pediatric rare disease nanoparticle nanomedicine |
| title | Nanotechnology for Pediatric Retinoblastoma Therapy |
| title_full | Nanotechnology for Pediatric Retinoblastoma Therapy |
| title_fullStr | Nanotechnology for Pediatric Retinoblastoma Therapy |
| title_full_unstemmed | Nanotechnology for Pediatric Retinoblastoma Therapy |
| title_short | Nanotechnology for Pediatric Retinoblastoma Therapy |
| title_sort | nanotechnology for pediatric retinoblastoma therapy |
| topic | retinoblastoma conventional chemotherapy cancer pediatric rare disease nanoparticle nanomedicine |
| url | https://www.mdpi.com/1424-8247/15/9/1087 |
| work_keys_str_mv | AT eleonorarusso nanotechnologyforpediatricretinoblastomatherapy AT andreaspallarossa nanotechnologyforpediatricretinoblastomatherapy AT brunotasso nanotechnologyforpediatricretinoblastomatherapy AT carlavilla nanotechnologyforpediatricretinoblastomatherapy AT chiarabrullo nanotechnologyforpediatricretinoblastomatherapy |